The shares of a Small-Cap company, specializing in the manufacturing of specialty chemicals, are in focus after the promoter sells 26,97,842 Lakh equity shares in two tranches.
With a market capitalization of Rs. 9,461.18 crores on Tuesday, the shares of Ami Organics Ltd declined by upto 3.1 percent, making a low of Rs. 1150.90 per share compared to its previous closing price of Rs. 1188.20 per share.
Ami Organics Ltd, in the manufacturing of specialty chemicals, recently experienced a bulk deal in which two individual investors, Nareshkumar Ramjibhai Patel and Chetankumar Chhaganlal Vaghasia, sold 26,97,842 Lakh equity shares in two tranches, at Rs. 1,115 per share. The total number of shares that changed hands was 53,95,684 Lakhs shares, which represents a 6.6 percent stake amounting to nearly Rs. 601.6 crore on May 19.
Along with this, Kotak Mahindra Mutual Fund also acquired a 6.6 percent stake in Ami Organics at a price of Rs. 1,115 per share, totaling approximately Rs. 601.6 crore, through open market transactions on May 19. Ace Investor Ashish Kacholia holds a stake of 1.72 percent in the company, which consists of 7,04,974 equity shares as of March 2024.
Financials & Others
Ami Organics is a leading Research and Development manufacturer of Specialty Chemicals that focuses on the development and manufacturing of Advanced Pharmaceutical Intermediates and Specialty Chemicals, It serves diverse end-use industries, including Pharmaceuticals, Cosmetics, Fine Chemicals, semiconductors, and Battery Chemicals, among others.
The company’s revenue rose by 38.8 percent from Rs. 226.3 crore to Rs. 314.26 crore in Q4FY24-25. Meanwhile, Net profit rose from Rs. 25.15 crore to Rs. 62.48 crore during the same period.
The company’s Revenue is driven by two segments, of which 85 percent of revenue is from Advanced Pharmaceutical Intermediates and 15 percent of revenue from Specialty Chemicals.
Written by Sridhar J
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
